Theralase Advanced Cancer Therapy Research Recognized at Major International Conference


Published on

Researchers have discovered a significant new mechanism of action for a new class of Photo Dynamic Compounds (PDCs), that have been custom designed to destroy cancer cells when activated by a proprietary light source.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Theralase Advanced Cancer Therapy Research Recognized at Major International Conference

  1. 1. Press ReleaseTheralase Advanced Cancer Therapy Research Recognized at MajorInternational ConferenceToronto, Ontario – May 16, 2013, Theralase Technologies Inc. (TSXV: TLT) (“Theralase”)announced today that its researchers have discovered a significant new mechanism ofaction for a new class of Photo Dynamic Compounds (PDCs), that have been customdesigned to destroy cancer cells when activated by a proprietary light source.The preclinical study, conducted by Theralase scientists and their colleagues at UniversityHealth Network’s Princess Margaret Cancer Centre, was presented on May 15, at theLaser World of Photonics conference held in Munich, Germany.In previous preclinical studies, Theralase’s PDCs have been proven to be promising anti-cancer agents in various cancer models. Their efficacy involved a number of criticalcellular processes, including DNA damage and programmed cell death. All PDCs werethought to work primarily by oxygen-dependent mechanisms, ultimately causing celldeath in the presence of highly reactive oxygen. In this study; however, scientistsestablished that a new class of Theralase PDCs have an additional “oxygen independent”mechanism of action, which would increase efficacy in the destruction of more clinicallyaggressive tumours.The research lead by Dr. Lothar Lilge, Senior Scientist, Ontario Cancer Institute, PrincessMargaret Cancer Centre and Dr. Arkady Mandel, Chief Scientific Officer, Theralase hasshown that specific metal-based PDCs when tested for effectiveness of cancer destructionin a low oxygen environment were proven to be highly effective in the destruction ofhuman brain cancer cells in-vitro, thus activating this newly discovered pathway.Additionally using this pathway, Theralase scientists confirmed in a preclinical model acomplete response rate and the destruction of subcutaneous (under the skin) coloncancer tumours in mice, which were treated with Theralase’s anti-cancer PDC technology.On follow-up, the initial complete response was maintained in two-thirds of the animalsfor over 1 year without recurrence.Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated,“Recognition of our world class anti-cancer research at the Munich conference is anothertestament to the cutting edge research our scientists are conducting in this field. Ourfindings would strongly suggest that Theralase’s PDCs oxygen independent potency wouldsignificantly enhance our ability to destroy cancer cells. Tumours in a low oxygenenvironment have been extremely challenging because this lack of oxygen renders solidtumours much more resistant to therapeutic interventions. Many traditional therapeuticagents, conducted on poorly oxygenated solid core tumours, including any currently FDAapproved PDCs, are susceptible to a “self-limiting” activity; whereby, below a criticalthreshold oxygenation level, their efficacy is progressively reduced resulting in minimal tono cancer cell destruction. This new class of Theralase PDCs are not susceptible to this
  2. 2. Press Release“self-limiting” activity and as a result maintain their efficacy even in extremely lowoxygenated cancerous tumours, such as breast and prostate cancer. As a result, Theralaseis extremely excited about the latest research and what it means in the field of cancerdestruction. Theralase is committed to the early commercialization of its patented lightactivated Photo Dynamic Compounds in the areas of anti-cancer and anti-bacterialapplications to generate substantial revenues for the Company and hence dramaticallyincrease shareholder value.”About Theralase Technologies Inc.Theralase Technologies Inc., founded in 1995, designs, develops, manufactures andmarkets patented, superpulsed laser technology utilized in biostimulation andbiodestruction applications. Theralase technology is safe and effective in treating pain,inflammation and for tissue regeneration of neural muscular skeletal conditions Theralaseis currently developing patented Photo Dynamic Compounds (PDCs) that are able totarget and destroy cancers, bacteria and viruses when light activated by Theralase’sproprietary laser technology.For further information please visit , regulatory filings may be viewedby visiting press release contains forward-looking statements, which reflect the Companys current expectationsregarding future events. The forward-looking statements involve risks and uncertainties. Actual results coulddiffer materially from those projected herein. The Company disclaims any obligation to update theseforward-looking statements.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies ofthe TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.For More Information, please contact:Roger Dumoulin-White,President & CEO416-699-LASE (5273) ext. 225rwhite@theralase.comKristina HacheyChief Financial Officer416-699-LASE (5273) ext. 224khachey@theralase.comGreg BewshDirector of Investor Relations416-699-LASE (5273) ext.
  3. 3. Press ReleaseArkady MandelChief Scientific Officer416-699-LASE (5273) ext.